Overview
Beovu is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic macular edema (DME), a common complication of diabetes that can lead to vision loss. Beovu may be prescribed to adults with DME to help reduce swelling in the retina and maintain or improve vision. Beovu is also known by its drug name, brolucizumab-dbll.

Beovu is a vascular endothelial growth factor (VEGF) inhibitor. It works by blocking VEGF, a protein that causes abnormal blood vessel growth and leakage in the retina, which can damage vision in people with diabetes.

How do I take it?
Prescribing information states that Beovu is typically administered by intravitreal injection (injection into the eye) once every six weeks for the first five doses. After that, it is typically given once every eight to 12 weeks, depending on how well the treatment is working. Beovu should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Beovu include blurred vision, cataract, conjunctival hemorrhage (bleeding on the white of the eye), eye pain, and vitreous floaters (spots in vision).

Rare but serious side effects may include endophthalmitis (a severe eye infection), retinal detachment (separation of the retina from the back of the eye), retinal vasculitis (inflammation of blood vessels in the retina), retinal vascular occlusion (blockage of blood flow in the retina), increased intraocular pressure (elevated pressure inside the eye), and arterial thromboembolic events (blood clots in arteries that may cause heart attack or stroke).

For more information about this treatment, visit:
Beovu (brolucizumab-dbll) Injection, for Intravitreal Use — Novartis Pharmaceuticals